SCHEMBL21295385

SCHEMBL21295385

COc1cccc(NC(=O)Nc2ccc(Oc3ccccc3)c(C)c2)c1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 1/20 0.64
TSHR P16473 1/20 0.64
MAPT P10636 8/20 0.63
RAB9A P51151 7/20 0.63
NPC1 O15118 6/20 0.63
SMN1; SMN2 Q16637 3/20 0.63
PGR P06401 1/20 0.63
AR P10275 1/20 0.63
KMT2A Q03164 4/20 0.60
ALDH1A1 P00352 3/20 0.60
MEN1 O00255 3/20 0.60
RAF1 P04049 1/20 0.60
MITF O75030 1/20 0.60
HTT P42858 3/20 0.57
LMNA P02545 1/20 0.57
MAPK1 P28482 1/20 0.57
STAT1 P42224 1/20 0.57
PKM P14618 1/20 0.56
NLRP3 Q96P20 1/20 0.56
PDGFRA P16234 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30743992 1.00 TP53 (0.64) TP53TSHRMAPTRAB9ANPC1
SCHEMBL21295431 0.91 STK39 (0.58) TP53TSHRMAPTRAB9ANPC1
SCHEMBL21305446 0.91 STK39 (0.60) TP53TSHRMAPTRAB9ANPC1
SCHEMBL30744028 0.91 STK39 (0.60) TP53TSHRMAPTRAB9ANPC1
SCHEMBL23051396 0.88 KMT2A (0.58) MAPTRAB9ANPC1SMN1; SMN2PGR
SCHEMBL21295375 0.88 TP53 (0.66) TP53TSHRMAPTRAB9ANPC1
SCHEMBL30743987 0.88 TP53 (0.66) TP53TSHRMAPTRAB9ANPC1
SCHEMBL21295336 0.88 MAPT (0.62) TP53MAPTRAB9ANPC1SMN1; SMN2
SCHEMBL30743994 0.88 MAPT (0.62) TP53MAPTRAB9ANPC1SMN1; SMN2
SCHEMBL21295549 0.86 MAPT (0.61) TP53TSHRMAPTRAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250214948-A1 TRIAZINE DERIVATIVES FOR TREATING DISEASES RELATING TO NEUROTROPHINS AlzeCure Pharma AB (SE) 2025-07-03 US disclosed
CN-111819172-B Triazine derivatives for the treatment of neurotrophin related diseases 阿泽克制药公司 2024-02-06 CN disclosed
EP-3759088-B1 TRIAZINE DERIVATIVES FOR TREATING DISEASES RELATING TO NEUROTROPHINS AlzeCure Pharma AB (SE) 2023-01-25 EP disclosed
EP-3759088-B1 TRIAZINE DERIVATIVES FOR TREATING DISEASES RELATING TO NEUROTROPHINS AlzeCure Pharma AB (SE) 2023-01-25 EP disclosed
US-20220306589-A1 TRIAZINE DERIVATIVES FOR TREATING DISEASES RELATING TO NEUROTROPHINS AlzeCure Pharma AB (SE) 2022-09-29 US disclosed
US-11352332-B2 Triazine derivatives for treating diseases relating to neurotrophins AlzeCure Pharma AB (SE) 2022-06-07 US disclosed
US-11352332-B2 Triazine derivatives for treating diseases relating to neurotrophins AlzeCure Pharma AB (SE) 2022-06-07 US disclosed
EP-3759088-A1 TRIAZINE DERIVATIVES FOR TREATING DISEASES RELATING TO NEUROTROPHINS Alzecure Pharma AB (SE) 2021-01-06 EP disclosed
US-20200399230-A1 TRIAZINE DERIVATIVES FOR TREATING DISEASES RELATING TO NEUROTROPHINS AlzeCure Pharma AB (SE) 2020-12-24 US disclosed
US-20200399230-A1 TRIAZINE DERIVATIVES FOR TREATING DISEASES RELATING TO NEUROTROPHINS AlzeCure Pharma AB (SE) 2020-12-24 US disclosed
CN-111819172-A Triazine derivatives for the treatment of neurotrophin-related disorders 阿泽克制药公司 2020-10-23 CN disclosed
WO-2019162702-A1 TRIAZINE DERIVATIVES FOR TREATING DISEASES RELATING TO NEUROTROPHINS AlzeCure Pharma AB (SE) 2019-08-29 WO disclosed
WO-2019162702-A1 TRIAZINE DERIVATIVES FOR TREATING DISEASES RELATING TO NEUROTROPHINS AlzeCure Pharma AB (SE) 2019-08-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220306589-A1 TRIAZINE DERIVATIVES FOR TREATING DISEASES RELATING TO NEUROTROPHINS NTRK2, BDNF, NGF TP53 2873/4885TSHR 144/4885MAPT 89/4885
US-20250214948-A1 TRIAZINE DERIVATIVES FOR TREATING DISEASES RELATING TO NEUROTROPHINS NTRK2, BDNF, NGF TP53 2873/4885TSHR 144/4885MAPT 89/4885
US-11352332-B2 Triazine derivatives for treating diseases relating to neurotrophins NTRK2, BDNF, NGF TP53 2709/4885TSHR 123/4885MAPT 79/4885
US-20200399230-A1 TRIAZINE DERIVATIVES FOR TREATING DISEASES RELATING TO NEUROTROPHINS NTRK2, BDNF, NGF TP53 2709/4885TSHR 123/4885MAPT 79/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.